Medicare Enrolled
Dr. Thomas Hutson, DO,PHARMD
Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Hutson from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Hutson?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Hutson
Dr. Thomas Hutson is a medical oncology specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Hutson performed 55,672 Medicare services across 2,351 unique beneficiaries.
Between the years covered by Open Payments, Dr. Hutson received a total of $1,108,613 from 30 pharmaceutical and/or device companies across 821 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Hutson is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 19% volume in TX
$1,108,613 industry payments
Medicare Practice Summary
Medicare Utilization ↗55,672
Medicare services
Top 19% in TX for medical oncology
2,351
Unique beneficiaries
$18
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,930 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 16,600 | $43 | $137 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
12,900 | $0 | $5 |
| Paclitaxel chemotherapy injection | 9,054 | $0 | $8 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
4,258 | $0 | $3 |
| Denosumab injection (Prolia/Xgeva) | 2,220 | $17 | $65 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,066 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,140 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 800 | $0 | $24 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
714 | $10 | $64 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
691 | $8 | $36 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
648 | $8 | $20 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
501 | $98 | $368 |
| Injection, leucovorin calcium, per 50 mg | 449 | $3 | $25 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
372 | $23 | $157 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 354 | $130 | $3,675 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
306 | $2 | $13 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
301 | $102 | $707 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
271 | $12 | $108 |
| PSA test (prostate cancer screening) | 256 | $18 | $94 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
190 | $2 | $300 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 182 | $3 | $373 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
164 | $61 | $250 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
114 | $26 | $145 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
96 | $1 | $7 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
88 | $52 | $344 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
86 | $1 | $6 |
| Piflufolastat F-18 diagnostic injection A diagnostic injection of the radioactive tracer piflufolastat F-18 used for imaging. The dose specified is 1 millicurie. |
83 | $573 | $1,536 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
67 | $1 | $8 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
64 | $23 | $161 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
60 | $7 | $431 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
59 | $49 | $313 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
48 | $2 | $19 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
43 | $11 | $96 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
41 | $50 | $821 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
34 | $16 | $94 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
33 | $176 | $1,067 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
33 | $135 | $500 |
| New patient office visit, complex (60-74 min) | 32 | $169 | $709 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
31 | $58 | $211 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
27 | $16 | $100 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
26 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
26 | $6 | $34 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
26 | $10 | $75 |
| Intravenous chemotherapy injection Chemotherapy medication is administered directly into a vein using a push technique. This method involves injecting the drug through a needle or catheter already placed in the vein. |
24 | $81 | $500 |
| CT scan of chest, without contrast A computed tomography scan of the chest area that uses X-rays to create detailed images without the use of contrast dye. |
20 | $40 | $686 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
18 | $44 | $289 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
17 | $142 | $496 |
| Reticulated platelet measurement A blood test that measures the level of young, newly formed platelets in the body. |
15 | $35 | $143 |
| CT scan of abdomen and pelvis, without contrast A computed tomography scan that creates detailed images of the abdominal and pelvic organs. The procedure is performed without the use of intravenous contrast dye. |
13 | $76 | $560 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
11 | $1,180 | $4,802 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.7% high complexity
92.0% medium
6.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,108,613
Total received (2018-2024)
Avg $158,373/year across 7 years
Top 2% in TX for medical oncology
30
Companies
821
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$904,358 (81.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$203,674 (18.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$582 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$31,067
2023
$119,734
2022
$169,006
2021
$180,791
2020
$166,716
2019
$244,858
2018
$196,441
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Exelixis Inc.
$198,221
PFIZER INC.
$166,903
EMD Serono, Inc.
$113,042
Astellas Pharma US Inc
$103,693
Janssen Biotech, Inc.
$103,012
Eisai Inc.
$66,612
Seagen Inc.
$53,134
E.R. Squibb & Sons, L.L.C.
$50,838
AstraZeneca Pharmaceuticals LP
$50,364
Merck Sharp & Dohme LLC
$47,854
EISAI INC.
$35,451
AVEO Pharmaceuticals, Inc.
$24,281
Gilead Sciences, Inc.
$22,906
Dendreon Pharmaceuticals LLC
$10,640
Clovis Oncology, Inc.
$9,841
Aveo Pharmaceuticals, Inc.
$8,815
GENZYME CORPORATION
$8,117
Merck Sharp & Dohme Corporation
$6,892
Eisai Co., Ltd.
$6,718
Seattle Genetics, Inc.
$6,110
Pfizer Inc.
$5,371
Bayer HealthCare Pharmaceuticals Inc.
$3,997
Janssen Scientific Affairs, LLC
$2,444
Bayer Healthcare Pharmaceuticals Inc.
$1,789
Progenics Pharmaceuticals, Inc.
$1,350
Sun Pharmaceutical Industries Inc.
$66
ABBVIE INC.
$65
Janssen Pharmaceuticals, Inc
$47
Myovant Sciences Inc.
$24
Pharmacyclics LLC, An AbbVie Company
$20
Top 3 companies account for 43.1% of total payments
Associated products mentioned in payments ›
BAVENCIO · Bavencio · CABOMETYX · Cabometyx · EPKINLY · ERLEADA · Erleada · FOTIVDA · IMBRUVICA · IMJUDO · INLYTA · JEVTANA · KEYTRUDA · LYNPARZA · Lenvima · Nubeqa · OPDIVO · ORGOVYX · PADCEV · PROVENGE · Padcev · Rubraca · SUTENT · TALZENNA · Trodelvy · XTANDI · Xofigo · Xtandi · YONSA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (82%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for medical oncology in TX.
Equivalent to $1,991 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
90
Per 100K population
3.5
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Hutson is a mixed practice specialist, with above-average Medicare volume (top 19% in TX), with speaking/promotional industry engagement in the top 2% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Hutson experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Hutson performed 16,600 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Hutson receive payments from pharmaceutical companies?
Yes. Dr. Hutson received a total of $1,108,613 from 30 companies across 821 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Hutson's costs compare to other medical oncologists in Dallas?
Dr. Hutson's average Medicare payment per service is $18. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Hutson) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Dallas
Browse medical oncologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology